180 related articles for article (PubMed ID: 30312551)
1. Cystic Fibrosis: Emerging Understanding and Therapies.
Rey MM; Bonk MP; Hadjiliadis D
Annu Rev Med; 2019 Jan; 70():197-210. PubMed ID: 30312551
[TBL] [Abstract][Full Text] [Related]
2. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
[TBL] [Abstract][Full Text] [Related]
3. Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.
Dilokthornsakul P; Patidar M; Campbell JD
Value Health; 2017 Dec; 20(10):1329-1335. PubMed ID: 29241892
[TBL] [Abstract][Full Text] [Related]
4. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Rehman A; Baloch NU; Janahi IA
N Engl J Med; 2015 Oct; 373(18):1783. PubMed ID: 26510035
[No Abstract] [Full Text] [Related]
5. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Wainwright CE; Elborn JS; Ramsey BW
N Engl J Med; 2015 Oct; 373(18):1783-4. PubMed ID: 26510034
[No Abstract] [Full Text] [Related]
6. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
7. A new chapter in therapy for cystic fibrosis.
Bilton D
Lancet Respir Med; 2015 Jul; 3(7):e20. PubMed ID: 26117158
[No Abstract] [Full Text] [Related]
8. [A milestone in cystic fibrosis therapy].
Reinhardt D
MMW Fortschr Med; 2015 Nov; 157(19):34. PubMed ID: 26953403
[No Abstract] [Full Text] [Related]
9. Another Beginning for Cystic Fibrosis Therapy.
Davis PB
N Engl J Med; 2015 Jul; 373(3):274-6. PubMed ID: 25981385
[No Abstract] [Full Text] [Related]
10. Drug combination that corrects deficient protein in cystic fibrosis improves lung function.
Mayor S
BMJ; 2015 May; 350():h2689. PubMed ID: 25990552
[No Abstract] [Full Text] [Related]
11. [Treatment of Cystic Fibrosis with CFTR Modulators].
Tümmler B
Pneumologie; 2016 May; 70(5):301-13. PubMed ID: 26894479
[TBL] [Abstract][Full Text] [Related]
12. The stony road to phe508del CFTR pharmacotherapy: smoothing the first rock.
Tümmler B
Lancet Respir Med; 2014 Jul; 2(7):508-9. PubMed ID: 24973279
[No Abstract] [Full Text] [Related]
13. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
[No Abstract] [Full Text] [Related]
14. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
[TBL] [Abstract][Full Text] [Related]
15. Tezacaftor/Ivacaftor (Symdeko) for cystic fibrosis.
Med Lett Drugs Ther; 2018 Oct; 60(1558):174-176. PubMed ID: 30335045
[No Abstract] [Full Text] [Related]
16. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
[TBL] [Abstract][Full Text] [Related]
17. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
[TBL] [Abstract][Full Text] [Related]
18. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
20. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
Schneider EK; Reyes-Ortega F; Li J; Velkov T
Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]